Literature DB >> 9670279

Assessing the economic value of anticancer therapies.

N Neymark1.   

Abstract

Mesh:

Substances:

Year:  1998        PMID: 9670279     DOI: 10.1007/978-3-642-72123-6

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


× No keyword cloud information.
  2 in total

1.  Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.

Authors:  Niels Neymark; Thierry Gorlia; Ines Adriaenssen; Benoit Baron; Martine Piccart
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  Comparing the costs of three prostate cancer follow-up strategies: a cost minimisation analysis.

Authors:  Alison M Pearce; Fay Ryan; Frances J Drummond; Audrey Alforque Thomas; Aileen Timmons; Linda Sharp
Journal:  Support Care Cancer       Date:  2015-08-06       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.